1. Remedy for improving ICC prognosis
- Author
-
Tatsuya Tsuji, Shigeharu Takai, Seiki Tashiro, Yuko Sumise, Hitomi Kamo, Hidenori Miyake, and Kazuo Yoshioka
- Subjects
Oncology ,medicine.medical_specialty ,Poor prognosis ,Carcinoma, Hepatocellular ,hepatitis virus ,lenvatinib ,General Biochemistry, Genetics and Molecular Biology ,Cholangiocarcinoma ,hepatocellular carcinoma (HCC) ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,In patient ,Radical surgery ,Surgical treatment ,Survival rate ,Intrahepatic Cholangiocarcinoma ,nibolumab ,Hepatitis virus ,intrahepatic cholangiocarcinoma (ICC) ,business.industry ,Liver Neoplasms ,General Medicine ,Prognosis ,Bile Ducts, Intrahepatic ,Bile Duct Neoplasms ,chemistry ,Lenvatinib ,business - Abstract
The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is still poor, and the 5-year survival rate in patients undergoing radical surgery (R0) is less than one-third. Since the prognosis depends mainly on tumor factors, so early diagnosis is necessary. To extend the survival time of these patients with a poor prognosis, cases of long-term survival were examined based on the results of our experiences and the literature. It was found that the hepatitis virus was highly involved in the carcinogenesis of ICC, and patients who were infected with hepatitis virus had rather good survival. J. Med. Invest. 68 : 15-21, February, 2021.
- Published
- 2021
- Full Text
- View/download PDF